Sergio Cifuentes/X
Apr 5, 2025, 13:21
Sergio Cifuentes: Clinical Impact of HER2-Low Status on Survival in mBRCA1/2 TNBC
Sergio Cifuentes, Cancer Research Project Manager at CENEIT México, shared a post on X about a recent paper authored by Furong Kou et al. in the ASCO Journal:
“HER2-Low in mBRCA1/2 TNBC:
– mBRCA1: 38.8% were HER2-low
- RFS: 90.3% vs 75.1%
- DRFS: 92.4% vs 76.5%
- OS: 94.6% vs 77.4%
Higher HRD in HER2-low.
– mBRCA2
No survival difference by HER2 status.“
Authors: Furong Kou et al.
The complete article is available on ASCO Journal.
More posts featuring Sergio Cifuentes on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 5, 2025, 13:21
Apr 5, 2025, 12:28
Apr 5, 2025, 12:08
Apr 5, 2025, 11:52
Apr 5, 2025, 11:36